Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Single- and Multiple-Ascending-Dose, Food Effect, and Midazolam DDI Study of S-723595 in Healthy Adults
jRCT2051200126Phase 1Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tlc-3595 (3 arms), sponsored by Shionogi & Co., Ltd. Primary endpoints: Safety and tolerability after single-dose S-723595 in Japanese healthy adults, Safety and tolerability after multiple-dose S-723595 in Japanese/Caucasian healthy adults and 1 more. Started Jan 2021; status: completed.
02
Drugs
tlc-3595
Beyond the preview
Go deeper on jRCT2051200126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051200126.